Skip to main content
Fig. 7 | Clinical Epigenetics

Fig. 7

From: Low expression of miR-182 caused by DNA hypermethylation accelerates acute lymphocyte leukemia development by targeting PBX3 and BCL2: miR-182 promoter methylation is a predictive marker for hypomethylation agents + BCL2 inhibitor venetoclax

Fig. 7

miR-182 promoter methylation is a predictive marker for DAC + Ven treatment. A miR-182 expression was analyzed in ALL cells with DNA hypermethylation or hypomethylation at the miR-182 promoter. B BCL2 protein levels were measured in five ALL samples with miR-182 promoter hypomethylation (hypo) and five ALL samples with hypermethylation (hyper). C–H Cell viability was measured in four ALL samples with miR-182 hypermethylation (C–F) and two ALL samples with hypomethylation (G and H) treated with Ven (0.1 μM) + DAC (5.0 μM) or either of them for 24 h. **P < 0.01; ***P < 0.001. N.S: not significant

Back to article page

Clinical Epigenetics

ISSN: 1868-7083

Contact us